Timothy Endy, MD, MPH, FACP, FIDSA, FASTMH

Dr. Endy is an international expert in the field of dengue and dengue hemorrhagic fever and emerging viral pathogens. Dr. Endy has conducted basic scientific research in the field of virology, developed
vaccine field and epidemiological study sites in Southeast and Central Asia, conducted phase I and II clinical vaccine trials and is active in the development and management of research programs that
are product oriented towards developing vaccines and diagnostics that meet U.S. Food and Drug Administration (FDA) regulatory requirements. Currently, Dr. Endy is the principal investigator for the
US Army’s Dengue Human Infection Model (DHIM), being developed at The State University of New York (SUNY) Upstate and a co-principal investigator for the clinical development of a heroin vaccine.
Dr. Endy is an active reviewer for peer reviewed journals, a subject matter expert on dengue and dengue vaccine development for industry partners, has published over 120 manuscripts and book chapters, and
is a National Institutes of Health (NIH) funded researcher conducting studies on dengue in Thailand. He is a board certified physician in the subspecialty of infectious diseases and internal medicine and
did his residency and fellowship training at the Walter Reed Army Medical Center, Washington, DC. Dr. Endy obtained his medical school training at the Uniformed Services University, F. Edward Herbert
School of Medicine, Bethesda, MD; received a Master of Public Health in Epidemiology from the University of Michigan, School of Public Health, Ann Arbor, MI; and a degree from the Pennsylvania
State University, University Park, PA. He served with distinction in the United States Army for 24 years and retired as a Colonel in 2006.